Business Wire

Global Survey Shows Industrywide Priority to Modernize Clinical Trials for Faster Study Execution

6.10.2020 14:03:00 EEST | Business Wire | Press release

Share

Modernizing clinical trial operations is a top priority among life sciences companies according to the Veeva 2020 Unified Clinical Operations Survey Report, one of the largest-ever global surveys of clinical operations professionals. Findings from Veeva Systems (NYSE: VEEV) reveal an industrywide drive to streamline processes for increased efficiency, quality, and speed in trials.

The shift to modernize has been well underway in major clinical areas such as eTMF, for example, where the number of respondents using eTMF has quadrupled since 2014 (68% vs. 17% in 2014). COVID-19 is now accelerating sponsor and CRO adoption of advanced applications to seamlessly manage trials and improve study performance. This research shows a significant opportunity to bring together clinical landscapes for faster execution, especially important as sponsors and CROs need to keep existing trials running and accelerate new trial starts.

Almost all sponsors and CROs report a need to unify their clinical applications, and most respondents (83%) now have initiatives planned or underway. The top drivers include better visibility and oversight, reduced manual processes, and improved study quality, underscoring the industry's need to streamline end-to-end clinical processes and simplify information sharing for better trial performance.

Streamlining Collaboration and Information Exchange

Sponsors, CROs, and sites share a large amount of timely information that impacts trial outcomes. An over-reliance on manual methods, such as email and paper shipments, creates significant challenges with tracking and reporting, manual processes, and misfiled/missing documents.

All respondents report the need to simplify information exchange with study partners, signaling an urgency to find easier and more connected ways to collaborate. Reducing manual processes (75%), greater visibility and oversight (58%), and faster study execution (58%) are among the top drivers to improve information sharing during trials.

Advanced Clinical Applications Becoming the Norm

Many organizations have made progress in modernizing clinical processes and systems by adopting purpose-built applications. eClinical solutions such as EDC (91%), eTMF (78%), and CTMS (64%), are utilized by most sponsors and CROs, as function-specific technologies to support clinical trials become the industry standard.

Those using advanced clinical applications are reporting significant benefits. Sponsors and CROs using purpose-built CTMS applications see considerable improvements in compliance with standards, governance and oversight, and study performance metrics and reporting. CTMS applications are the most effective tool for managing end-to-end clinical trial processes compared with homegrown systems and manual spreadsheets.

Consistent with the industry's effort to streamline information sharing, more than one-third of respondents say faster collection of site essential documents and easier collaboration will improve study start-up. Manual processes like email and paper shipments to exchange trial documents with sites cause delays. Automating areas like contracts and budgets and site essential document collection are key to accelerating trials.

"Life sciences companies recognize the significant opportunity to improve how trials are run and are modernizing their clinical operations," said Jim Reilly, vice president, Vault R&D at Veeva Systems. "COVID-19 is accelerating the transition to more connected ways of working that will have a long-term positive impact on the efficiency and speed of drug development."

The Veeva 2020 Unified Clinical Operations Survey Report examines the life sciences industry's progress toward modernizing clinical operations by gathering the experiences and opinions of more than 500 clinical operations professionals from around the globe. The annual research details the drivers, barriers, and benefits of a unified clinical operating model and tracks the industry's progress in its move to unify clinical trial systems and processes, and increase stakeholder engagement throughout study execution. The full report is available online at veeva.com/ClinicalSurvey.

About Veeva Systems

Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

Research Highlights
Veeva 2020 Unified Clinical Operations Survey Report

The report examines the life sciences industry's progress toward modernizing clinical operations by gathering the experiences and opinions of more than 500 clinical operations professionals globally. The research details the drivers, barriers, and benefits of a unified clinical operating model and tracks the industry's progress in its move to unify clinical trial systems and processes, and increase stakeholder engagement throughout study execution.

Modernizing Clinical Operations to Speed Study Execution

  • Most sponsors and CROs now utilize standalone, eClinical applications as they steadily adopt function-specific technologies to support clinical trials including, EDC (91%), eTMF (78%), and CTMS (64%).
  • Nearly all (98%) respondents say they have significant challenges with their clinical applications. The top three challenges – integrating multiple applications (70%), managing trial information across applications (57%), and reporting across multiple applications (56%) – are likely the result of system and process silos.
  • Most (98%) report the need to unify clinical applications, and 83% say their organizations now have initiatives planned or underway.
  • The need to unify clinical application landscapes is driven by better visibility and oversight (70%), reduced manual processes (69%), improved study quality (60%), faster study execution (56%), and improved collaboration (52%).

Improving the Flow of Information in Trials for Better Collaboration

  • All (100%) respondents say they need to improve information sharing between study partners to reduce manual processes (75%), improve visibility and oversight (58%), and speed trials (58%).
  • Email is the predominant way sponsors and CROs exchange information with sites (78%), followed by paper shipments (40%), and portals (38%).
  • Nearly all (99%) report significant challenges with the methods used to exchange information during clinical trials.
  • Managing information exchange via email and other traditional methods contribute to issues respondents have with tracking and reporting (67%), manual processes (64%), and misfiled/missing documents (53%).

Streamlining Study Start-up to Accelerate Cycle Times

  • All (100%) respondents say they need to improve study start-up processes.
  • More than one-third say faster collection of site essential documents (44%) and easier collaboration (42%) will improve study start-up, highlighting the importance of streamlined information sharing and collaboration to trial performance.
  • Majorities (81%) use spreadsheets to manage study start-up processes. Roughly half use eTMF (52%) and CTMS (50%) applications.

Digitizing Trial Processes for Higher Quality Results

  • The number of respondents using an eTMF application has quadrupled since 2014 (68% vs. 17% in 2014). The growth in eTMF adoption comes as organizations increasingly move away from general-purpose methods to manage TMF processes.
  • Sponsors and CROS using advanced CTMS applications to manage clinical studies report significant advantages over manual processes and other systems, including compliance with standards (58% versus 37%, respectively), governance and oversight (48% versus 38%, respectively), and study performance metrics and reporting (46% versus 32%, respectively).

® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com

Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Xsolla to Showcase New Brand With All the Things for Developers to Go Direct-to-Consumer at DICE Summit 2026, Empowering Developers to Launch, Grow, and Win9.2.2026 23:00:00 EET | Press release

Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its participation in the DICE (Design, Innovate, Communicate, Entertain) Summit 2026, taking place February 10-12 at the ARIA Resort & Casino in Las Vegas. As the industry's premier gathering of creative minds and thought leaders dedicated to community building and advancing interactive entertainment, DICE Summit provides the ideal venue for Xsolla to collaborate and showcase how its comprehensive platform delivers everything developers need to power video game commerce and build successful direct-to-consumer businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209768772/en/ (Graphic: Xsolla) DICE Summit brings together industry leaders, innovative developers, and creative visionaries to explore new approaches to game development and artistic expression. Xsolla's presence at the event underscore

Xsolla Brings Mobile-First Monetization Expertise to Gamesforum Barcelona 2026, Where Europe's Mobile Gaming Leaders Gather to Solve the Industry's Toughest Growth Challenges9.2.2026 21:30:00 EET | Press release

Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its participation in Gamesforum Barcelona 2026, taking place Feb.10-11 at the InterContinental Hotel in Barcelona. This event brings together Europe's sharpest minds in mobile gaming for practical, data-driven sessions focused on what actually works in today's hypercompetitive mobile landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209301026/en/ (Graphic: Xsolla) With over 600 professionals from Europe's top publishers, ad networks, and studios in attendance, Gamesforum Barcelona has earned its reputation as the place where mobile gaming's most pressing problems get solved: How do you scale profitably? How do you retain players in saturated markets? How do you monetize without alienating your audience? "Gamesforum Barcelona represents everything we value about the European mobile gaming commu

Beast Industries Acquires Step, Expanding its Platform to Include Financial Services9.2.2026 19:30:00 EET | Press release

Beast Industries, the largest and most innovative creator based platform in the world, today announced the acquisition of Step, a financial technology company dedicated to making financial literacy and money management accessible to all. This acquisition marks a significant milestone for Beast Industries, bringing together Step's robust technology platform and full-stack fintech team with Beast Industries’ extensive audience reach and proven track record in philanthropic initiatives. Together, the combined organization will deliver innovative solutions that make financial wellness achievable for people at every step of their life journey. "Financial health is fundamental to overall wellbeing, yet too many people lack access to the tools and knowledge they need to build financial security," said Jeff Housenbold, CEO of Beast Industries. "This acquisition positions us to meet our audiences where they are, with practical, technology-driven solutions that can transform their financial futu

Align Partners Issues Public Shareholder Letter and Submits Formal Shareholder Proposals to DB Insurance9.2.2026 16:26:00 EET | Press release

Align Partners Capital Management Inc. (“Align Partners”), a shareholder of DB Insurance Co., Ltd. (KRX:005830) (“DBI” or the “Company”) holding 1.9%, has issued a public shareholder letter to DBI’s Board of Directors aimed at strengthening capital allocation policy and governance oversight, and submitted formal shareholder proposals for the 2026 Annual General Meeting (“AGM”). Despite DBI’s robust fundamentals—including a 16.1% ROE and a 226% K-ICS ratio—the Company trades at an adjusted PBR of 0.40x, representing a severe 60% discount to its Comprehensive Equity under IFRS17. Align Partners identifies inefficient capital allocation and a lack of independent governance oversight as primary drivers of this persistent undervaluation. The letter notes that DBI’s Return on Required Capital (ROR) of 21.2% significantly lags behind domestic and global peers, reflecting a historical focus on top-line growth over risk-adjusted profitability. This is exacerbated by a passive payout policy and

Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 20269.2.2026 14:00:00 EET | Press release

Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins. The TarSeer™ BRETSA™ Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. It gives drug discovery researchers early, target-specific cellular insights by validating weak or early chemical matter and expanding the targets accessible in live-cell drug discovery workflows. The technology will be debuted at the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, February 7-11, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206015371/en/ “You can now potentially study intracellular target engagement for any protein in live cells,” says M

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye